A top Trump administration health official has said that as many as 19 therapeutics trial are underway and 211 in planning stages in a bid to find the cure for coronavirus.
We are leaving no stone unturned to find the treatment for COVID-19... We don't have any approved therapeutics for COVID-19 but we are actively involved with the academic, commercial and private sector to find it, FDA Commissioner Stephen M Hahn told reporters at a White House news conference.
Seventy-two trials of therapeutics are underway in the United States under FDA oversight and 211 are in the planning stages, so we expect to see more. This includes convalescent plasma as well as antiviral therapies, Hahn added.
According to Hahn, work is continuing on finding a vaccine. FDA has authorised two firms on vaccine trials.
Hahn said that the FDA has told manufacturers that in order to market anti-body tests in the US, they have to validate their tests.
They have to tell us that they validated their tests, and in the package insert they have to let people know, end users, labs etc., that those tests were not authorised by FDA, he said.
So far, the US has authorised four and more are in the pipeline, he added.
Antibody tests that are used to detect natural immunity and the FDA's approach to help make these tests available, he noted.
These are just one part of FDA's larger response effort. They can play a role in helping move the economy forward by helping healthcare professionals identify those who have immunity to the COVID-19, he asserted.
During the COVID-19 pandemic, the FDA has worked with more than 380 test developers who have said they will be submitting emergency use authorisations (EUA) requests to FDA for tests that detect the virus.
To date, the FDA has issued 44 individual emergency use authorisations for test kit manufacturers and laboratories.
In addition, 19 authorised tests have been added to the EUA letter of authorisation for high complexity molecular-based laboratory developed tests (LDTs).
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
